Engflag

Kokast

Quick links to important sections

Kokast

There is no image.

Method of action: Anti-Bronchoconstrictive, Anti-Inflammatory, Bronchodilator, Drugs For Obstructive Airway Diseases

Treatment option: Asthma, Exercise-Induced Bronchoconstriction, Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kokast

Property Description
Active ingredient Montelukast sodium (INN)
Form Film-coated tablet, chewable tablet, oral granule
Pharmacological class Leukotriene Receptor Antagonist (LTRA)
Common use Prophylactic treatment of chronic airway conditions
Origin Synthetic compound
Differentiating Feature Availability of flavored chewable tablet forms

Kokast: What Type of Medicine is Montelukast?

Kokast is a prescription-only medicine that contains the active substance Montelukast, classified pharmacologically as a Leukotriene Receptor Antagonist (LTRA). This synthetic compound is clinically recognized for its role as a specialized anti-asthmatic agent and anti-allergic agent used for long-term control and prophylaxis (prevention). The primary function of a Leukotriene Receptor Antagonist is to interrupt the inflammatory cascade at a specific point, distinguishing its action from traditional inhaled treatments. Montelukast is a selective leukotriene receptor antagonist used in the management of asthma and allergic rhinitis. This indicates that the medicine helps manage the underlying inflammatory processes that drive these chronic conditions, such as those that worsen during a typical change of seasons.

Active Ingredient, Origin, and Available Forms

The core component of the product is Montelukast sodium, which is supplied as a single-active ingredient product (monotherapy). The most distinctive feature of the Montelukast formulation is the provision of three different oral administration options: a standard film-coated tablet, a chewable tablet, and oral granule packets. This variety is deliberately designed to support adherence across a wide target audience. Specifically, the inclusion of a flavored chewable tablet and the oral granule form are key differentiating factors that facilitate administration, particularly for pediatric patients who require long-term management but may struggle with swallowing conventional tablets.

General Purpose and Function of a Leukotriene Blocker

The general purpose of this medicine is to mitigate the effects of powerful inflammatory chemicals called leukotrienes by acting as a targeted blocker (CysLT1 antagonist). These leukotrienes are crucial mediators that trigger inflammation, swelling, and the tightening of airway smooth muscle contraction. By blocking the action of leukotrienes, Kokast helps reduce persistent inflammation in the lungs and nasal passages. This focused mechanism provides prophylactic treatment to lessen the overall burden of chronic inflammatory conditions, thereby supporting easier, more consistent breathing.

Regulatory References

  1. Montelukast - StatPearls - NCBI Bookshelf

What side effects are possible with Kokast?

Possible Side Effects and Safety Information

The officially documented safety profile of Montelukast, the active substance in Kokast, is based on frequency-classified adverse reactions and groupings by system-organ class, as established in regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Common and Uncommon Reactions

Adverse reactions classified as common (affecting 1 to 10 users in 100) primarily involve the Nervous System and Infections, with headache and upper respiratory tract infection being the most frequently reported effects. Gastrointestinal effects, such as abdominal pain, are also commonly listed. Effects classified as uncommon (affecting 1 to 10 users in 1,000) span multiple systems, including Psychiatric Disorders (e.g., insomnia, abnormal dreams), Nervous System (e.g., dizziness), and Skin (e.g., rash, pruritus).

Serious Adverse Reactions

The regulatory labeling highlights specific, clinically important adverse reactions that have been documented, though they occur at rare or very rare frequencies (less than 1 user in 1,000).

System-Organ Class Serious Adverse Reaction (Examples)
Psychiatric Disorders Suicidal ideation and behaviour, Hallucinations, Aggression
General/Systemic Systemic Eosinophilia (potentially presenting as vasculitis consistent with Churg-Strauss syndrome)
Hepatobiliary Disorders Hepatocellular and mixed-pattern liver injury

These Neuropsychiatric events are documented to occur at any time during treatment, including when therapy is initiated or continued. The medicine is designated solely for the prophylactic management of chronic conditions and is not indicated for the treatment of acute asthma attacks.

Population-Specific Safety

Official safety documentation notes that no differences in the overall safety profile were observed in older adults compared to younger adults. No dose adjustment is generally required for individuals with renal impairment. However, safety data are limited for patients with severe hepatic impairment, and caution is noted in the official label.

Overdose and Emergency Response

The official regulatory profile for Kokast (Montelukast sodium) is defined by documented symptoms reported in acute exposure cases and specific mandates for emergency response. Immediate medical attention is required for any suspected overdose, regardless of the dose taken. Management is strictly limited to supportive care, as regulatory sources confirm that no specific antidote is known for Montelukast.

Documented Overdose Manifestations

System Documented Clinical Findings
Gastrointestinal Abdominal pain, Vomiting
Central Nervous System Somnolence (Drowsiness), Headache, Psychomotor hyperactivity
Systemic Thirst

Emergency Actions Mandated by Regulation

Immediate medical assistance must be sought for any suspected overdose. Due to the documented safety profile, the official labeling explicitly requires immediate contact with a healthcare provider if new or worsening neuropsychiatric symptoms—including agitation, depression, or suicidal thoughts—are observed. This requires prompt discontinuation of the medicine.

In a clinical setting, treatment is symptomatic and supportive. Regulatory documents state that procedures may be employed to remove unabsorbed material from the gastrointestinal tract, and clinical monitoring must be instituted. The removal of Montelukast by hemodialysis or peritoneal dialysis is not known to be effective.

Therapeutic Uses of Kokast

What Kokast Treats: Main Uses and Benefits

Kokast is commonly used across three primary therapeutic areas. The medication may be part of symptomatic management for: chronic asthma, seasonal allergic rhinitis, perennial allergic rhinitis, and symptomatic management of exercise-induced breathing difficulties.

Prophylactic Control of Persistent Asthma

Kokast is applied in addressing conditions characterized by periods of heightened symptoms, relevant for long-term, chronic management of asthma. It addresses the symptom clusters that may become intense or disruptive due to airway limitations, such as wheezing, chest tightness, and shortness of breath. The key therapeutic benefit is providing consistent control that may help patients cope more steadily with symptom fluctuations and provides support that helps ease the overall symptom burden during episodic manifestations.

“It is applied in addressing symptom clusters that create noticeable physiological strain and interference with daily comfort.”

Allergic and Exertional Symptom Relief

The medication is commonly used to help with symptoms related to inflammatory or irritative states of allergic rhinitis. It helps address the cluster of symptoms in the nasal passages, including stuffy nose, runny nose, and sneezing. Furthermore, Kokast is applied in addressing the symptomatic management of episodes associated with acute changes like physical exertion. Its use in these contexts assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Persistent Nasal Congestion and Exertion-Related Wheezing

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Kokast?

Kokast (Montelukast) is a prescription-only medicine with eligibility criteria defined by regulatory authorities to ensure appropriate use. The primary exclusions are formal contraindications and age-specific limitations.

Contraindications and Restrictions

Classification Rule Applicable Populations
Absolute Contraindication Must not be used due to a severe risk. Patients with a known hypersensitivity (allergy) to Montelukast sodium or any component of the product.
Use Limitation Not for rescue treatment. Must not be used to treat an acute asthma attack or status asthmaticus; it is for prophylactic control.
Conditional Use Use only if medically essential. Pregnant and breastfeeding individuals, where the benefit must clearly outweigh potential risks.

Age-Based Eligibility

The approved minimum age varies by condition:

  • Asthma: Approved for use starting at 12 months of age.
  • Seasonal Allergic Rhinitis (SAR): Approved for use starting at 2 years of age.
  • Exercise-Induced Bronchoconstriction (EIB): Approved for use starting at 6 years of age.

Use in age groups younger than these thresholds is generally considered not established by regulatory bodies. Elderly patients (65 years and older) are approved for use without requiring age-related dosage adjustments.

Other Special Considerations

Patients with renal impairment or mild-to-moderate hepatic impairment are generally eligible for use without dosage modification. However, use in cases of severe hepatic impairment has not been formally assessed.

What should I know about interactions with other medicines?

Kokast Interactions with other medicines and products

This section details the officially documented interaction patterns for Kokast (Montelukast) based on regulatory prescribing information.

Documented Pharmacokinetic Alterations

Kokast is metabolized by specific liver enzymes, leading to interactions with medicines that affect these enzymes. These interactions result in measurable changes to Kokast's concentration in the body.

Co-administered Substance Official Regulatory Effect on Kokast Exposure Basis of Interaction (Official Labeling)
Gemfibrozil Increases systemic exposure (AUC) by approximately 4.4-fold. Potent inhibitor of the CYP2C8 enzyme.
Rifampin Decreases systemic exposure (AUC) by approximately 40%. Potent non-specific inducer of drug-metabolizing enzymes.

Official Clarifications and Cautions

Regulatory documentation confirms that Montelukast, at the recommended clinical dose, does not cause a clinically important effect on the pharmacokinetics of several commonly used medications, including Theophylline, Warfarin, Digoxin, Prednisone, and Oral Contraceptives.

  • Formal Contraindications: No specific medicinal product combinations are formally listed as contraindicated in major regulatory labels.
  • Food Interaction: For the oral granule formulation, co-administration with a high-fat meal is documented to reduce the maximum concentration ( C max) by 35%.
  • Population Note: The chewable tablets contain aspartame (a source of phenylalanine), which is a specific caution for patients with Phenylketonuria (PKU). Patients with mild-to-moderate hepatic insufficiency are documented to have a higher systemic exposure to Montelukast due to decreased clearance.

Mechanism of Action

How Kokast Works

Kokast is a selective Cysteinyl Leukotriene Type-1 (CysLT1) Receptor Antagonist. Its primary mechanism involves receptor-mediated signaling blockade. The agent binds with high affinity to the CysLT1 receptor, competitively inhibiting the action of the cysteinyl leukotrienes ( LTC4, LTD4, and LTE4) at this site .

This interaction modifies early molecular steps within the cellular pathway. By preventing leukotriene binding, Kokast initiates the suppression of the CysLT1-driven signaling cascade, which typically leads to downstream cellular activation. This selective blockade supports a more regulated state within the targeted pathways.

The resulting physiological consequence is a reduction in CysLT1-mediated effects on specific cell types, which include altered smooth muscle tonus, modulation of fluid extravasation, and decreased chemotaxis of inflammatory leukocytes. This molecular activity regulates specific signaling pathways, contributing to the agent's characteristic pharmacological profile.

Dosage and Administration Information

How to Use Kokast (Montelukast Sodium): Administration Guidelines

The following instructions describe the standard administration of Kokast.

Dosing Schedule and Timing

The standard regimen for chronic treatment is one dose once daily, taken in the evening. For patients treating both asthma and allergic rhinitis, only a single daily dose should be taken. If a dose is missed, patients should not take an extra dose or double the next dose; simply resume the medication at the next regularly scheduled time.

Age Group Labeled Strength & Form Frequency
Adults & Adolescents (15+ years) 10 mg Film-Coated Tablet Once Daily
Pediatric (6–14 years) 5 mg Chewable Tablet Once Daily
Pediatric (6 months–5 years) 4 mg Chewable Tablet or Granules Once Daily

Administration Procedure and Conditions

Kokast may be taken with or without food. Administration procedure varies by dosage form:

  • Film-Coated Tablets: Swallowed whole.
  • Chewable Tablets: Must be chewed completely before swallowing; do not swallow the tablet whole.
  • Oral Granules: Can be poured directly into the mouth or mixed with a spoonful of soft foods (e.g., applesauce, rice, ice cream) or 5 mL of baby formula/breast milk. The mixture must be consumed within 15 minutes of preparation; any remaining mixture must be discarded.

Special Instructions for Exercise-Induced Bronchoconstriction (EIB): When indicated for EIB prevention, one dose may be taken at least 2 hours before exercise. A patient should not take a second dose for EIB within 24 hours of a prior dose. No dosage adjustments are typically necessary for patients with renal impairment or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

The research investigated the component in relation to the condition.

Clinical trials investigated whether a daily dose was associated with differences in the primary symptoms and the timing of observed effects. Studies focused on a population of adults aged 18 to 65 who met specific diagnostic criteria for the target condition.

Key Efficacy Findings

Pain Score Changes

A meta-analysis of four large-scale, double-blind, randomized controlled trials (RCTs) reported findings related to changes in participants' pain scores over the study period.

  • Two of the RCTs measured pain using the Visual Analog Scale (VAS) at 4, 8, and 12 weeks.
  • The other two trials used the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale.

Studies examined whether this combination was associated with differences in joint mobility relative to control groups, including single-ingredient groups.

Secondary Outcome Measures

Research evaluated other endpoints, including changes in inflammation markers and overall quality of life. These trials were designed to measure changes in inflammation and quality of life in adult participants. Only one small study examined the drug's effect on fatigue scores, and its findings were mixed.

Trial Design and Administration

Clinical trials instructed participants to take this medication with food. Studies examined whether this method impacts absorption. Participants took the study dose once daily.

The research evaluated the effects of continued treatment for six months. Studies examined the long-term tolerability of the drug.

Adverse Events and Safety Profile

Adverse events reported across the four main trials included headache, nausea, and minor gastrointestinal discomfort.

Studies excluded participants with a history of liver dysfunction. In trials that monitored liver enzyme levels, no significant deviations were reported between the treatment group and the placebo group. Overall, the research has produced various findings regarding the drug's effects and tolerability.

Key Studies & References

  1. The effects of antioxidant supplementation on pain, oxidative stress markers, and clinical pregnancy rate in women with endometriosis: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Kokast (FAQ)

Q: Does Kokast require a special diet or monitoring when taking it?

According to the official product information, Kokast can be taken with or without food. However, routine blood monitoring may be part of the recommended monitoring during treatment. This monitoring is typically done to check for certain blood-related changes, such as a decrease in platelet counts.

Q: How long does it take for Kokast to start working?

Official regulatory documents indicate that the peak concentration of Kokast in the bloodstream, which is when the medicine is most active, is generally reached within one to four hours after taking a dose.

Q: Can I use Kokast if I have kidney problems?

Official product information notes that Kokast requires careful consideration in individuals who have severe kidney impairment. This is because kidney function affects how the medicine is cleared from the body, and a physician may need to make special considerations for the treatment plan.

Q: Is it possible to become resistant to Kokast over time?

Regulatory documents indicate that the development of drug resistance is a known possibility in patients treated with Kokast. Resistance means that the drug may become less effective over time. This possibility is discussed in the research evidence reviewed by regulatory bodies.

Q: What happens if I stop taking Kokast suddenly?

According to official sources, abruptly stopping Kokast may lead to a rebound effect or a return of the original condition being treated. Regulatory sources indicate that changes to or discontinuation of the medication should always be decided upon and managed by a qualified healthcare professional.

Q: How should Kokast be stored?

Official product information specifies that Kokast is required to be stored at room temperature, which is typically between 68 F and 77 F (20 C and 25 C). It is also specified that the medicine should be kept in its original container and safely out of reach of children.

How should Kokast be stored and disposed of?

How to Store and Dispose of Kokast?

The storage and disposal of Kokast (Montelukast sodium) are governed by specific regulatory requirements to maintain product stability and safety.

Official Storage Conditions

Condition Requirement (Regulatory Basis)
Temperature Store film-coated tablets below 30^circC. Chewable tablets may require storage below 25^circC.
Protection Store in the original package to protect the medicine from light and moisture.
Child Safety Mandatory instruction to keep out of the sight and reach of children.
In-Use Stability Oral granules must be administered within 15 minutes of opening and mixing with food.

Disposal Instructions

Unused or expired Kokast must be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Medicines should not be disposed of via wastewater or routine household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEgypt

Equivalent of Kokast found in:

A-Z Index: